Vitiligo overview: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:
==Diagnosis==
==Diagnosis==
===History and Symptoms===
===History and Symptoms===
 
[[Vitiligo]] is an [[asymptomatic]] disease that commonly presents during the second decade of life, with a gradual [[depigmentation]] over time.<ref>{{cite book | last = Soutor | first = Carol | title = Clinical dermatology | publisher = McGraw-Hill Education/Lange Medical Books | location = New York | year = 2013 | isbn = 978-0-07-177296-9 }}</ref><ref name="TaïebPicardo2007">{{cite journal|last1=Taïeb|first1=Alain|last2=Picardo|first2=Mauro|title=The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force|journal=Pigment Cell Research|volume=20|issue=1|year=2007|pages=27–35|issn=0893-5785|doi=10.1111/j.1600-0749.2006.00355.x}}</ref>
[[Vitiligo]] commonly presents during the second decade of life, with a gradual [[depigmentation]] over time. <ref>{{cite book | last = Soutor | first = Carol | title = Clinical dermatology | publisher = McGraw-Hill Education/Lange Medical Books | location = New York | year = 2013 | isbn = 978-0-07-177296-9 }}</ref><ref name="TaïebPicardo2007">{{cite journal|last1=Taïeb|first1=Alain|last2=Picardo|first2=Mauro|title=The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force|journal=Pigment Cell Research|volume=20|issue=1|year=2007|pages=27–35|issn=0893-5785|doi=10.1111/j.1600-0749.2006.00355.x}}</ref>


===Physical Examination===
===Physical Examination===

Revision as of 23:10, 25 June 2014

Vitiligo Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vitiligo from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Case Studies

Case #1

Vitiligo overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vitiligo overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Vitiligo overview

CDC on Vitiligo overview

Vitiligo overview in the news

Blogs on Vitiligo overview

Directions to Hospitals Treating Vitiligo

Risk calculators and risk factors for Vitiligo overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Vitiligo (IPA Template:IPA) or leukoderma is a chronic skin condition that causes loss of pigment, resulting in irregular pale patches of skin. The precise cause of vitiligo is complex and not fully understood. There is some evidence suggesting it is caused by a combination of auto-immune, genetic, and environmental factors. The population incidence in the United States is considered to be 1%.

Historical Perspective

Classification

Vitiligo can be classified in two clinical subtypes. One is segmented vitiligo, which affects only 1 segment of the body (face, arm or leg); and non-segmented vitiligo, involving more than 1 segment, such as both knees or both hands.

Pathophysiology

Causes

Differentiating Vitiligo from other Diseases

There are many conditions that are included in the differential diagnosis of vitiligo, the most common are pityriasis alba, postinflammatory hypopigmentation, tinea versicolor, halo nevus, tuberous sclerosis and albinism.

Epidemiology and Demographics

Vitiligo is the most common human pigmentation disorder, with a prevalence of 1,000/100,000 (1%) of the population. Males and females are equally affected. Half of patients are diagnosed before the age of 20.

Risk Factors

Autoimmune diseases and a family history of vitiligo are considered risk factors for developing this condition. A patient that has a relative with vitiligo has an increased risk of developing the disease and having an earlier onset.

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Vitiligo is an asymptomatic disease that commonly presents during the second decade of life, with a gradual depigmentation over time.[1][2]

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Support organizations

Support groups and organizations are available to help people learn more about vitiligo, understand treatment options, and find support from other people with vitiligo.

Vitiligo Support International is the largest vitiligo organization in the world. The nonprofit organization provides free access to online message boards, chat rooms, frequently asked questions, information and articles, as well as a patient-referred doctor search. The group advocates on behalf of patients, conducts patient conferences and has local support groups.

The National Vitiligo Foundation (NVF) is a 501(c)(3) nonprofit organization that provides access to online resources, physician listings, frequently asked questions (etc); funds research through grants and sponsors local support groups and workshop style conferences.

The American Vitiligo Research Foundation Inc. (AVRF) is a non-profit, tax-exempt charity that aims to increase public awareness about vitiligo and to help those affected by vitiligo, focusing specifically on children and their families. It supports finding a cure through alternatives to animal testing.

VITFriends,LLC is a support group in the North East USA. Formed in 2004, VITFriends is still growing and touching the world. We are a web-community offering words of encouragement and sharing hope to individuals dealing with Vitiligo. The goals is to bring public awareness about this condition as we share HOPE.[2]

References

  1. Soutor, Carol (2013). Clinical dermatology. New York: McGraw-Hill Education/Lange Medical Books. ISBN 978-0-07-177296-9.
  2. Taïeb, Alain; Picardo, Mauro (2007). "The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force". Pigment Cell Research. 20 (1): 27–35. doi:10.1111/j.1600-0749.2006.00355.x. ISSN 0893-5785.

Template:WH Template:WS